Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat

International Journal of Pharmaceutics

Volumn 419, Issue 1-2, 2011, Pages 339-346

  Wang, Xue Qing ^a   Fan, Jie Ming ^a   Liu, Ya Ou ^b   Zhao, Bo ^a   Jia, Zeng Rong ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Nanomatrix; Oral bioavailability; pH sensitive nanoparticles; Sorafenib; Suspension

Indexed keywords

NANOPARTICLE; POLYMER; SORAFENIB;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; MALE; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUSPENSION;

ADHESIVENESS; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZENESULFONATES; BIOLOGICAL AVAILABILITY; HYDROGEN-ION CONCENTRATION; MALE; NANOPARTICLES; NANOSTRUCTURES; POLYMETHACRYLIC ACIDS; POROSITY; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SILICON DIOXIDE; SOLUBILITY; SUSPENSIONS;

EID: 80053561797     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.08.003     Document Type: Article

References (28)

1. B. Blanchet, B. Billemont, J. Cramard, A.S. Benichou, S. Chhun, L. Harcouet, S. Ropert, A. Dauphin, F. Goldwasser, and M. Tod Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice J. Pharm. Biomed. Anal. 49 2009 1109 1114
2. M. Chacón, J. Molpeceres, L. Berges, M. Guzmán, and M.R. Aberturas Stability and freeze-drying of cyclosporine loaded poly(d,l lactide-glycolide) carriers Eur. J. Pharm. Sci. 8 1999 99 107 (Pubitemid 29189155)
3. Y.S. Chang, J. Adnane, P.A. Trail, J. Levy, A. Henderson, D. Xue, E. Bortolon, M. Ichetovkin, C. Chen, A. McNabola, D. Wilkie, C.A. Carter, I.C. Taylor, M. Lynch, and S. Wilhelm Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models Cancer Chemother. Pharmacol. 59 2007 561 574 (Pubitemid 46295136)
4. J.D. Dai, T. Zhang, X.Q. Wang, M. Meng, and Q. Zhang Lyophilization effect on the particle size stability of cyclosporine A pH sensitive nanoparticles Chin. J. Pharm. 36 2005 548 550
5. J.D. Dai, T. Nagai, X.Q. Wang, T. Zhang, M. Meng, and Q. Zhang pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A Int. J. Pharm. 280 2004 229 240 (Pubitemid 38950919)
6. D. Douroumis, and A. Fahr Nano- and micro-particulate formulations of poorly water-soluble drugs by using a novel optimized technique Eur. J. Pharm. Biopharm. 63 2006 173 175 (Pubitemid 43776205)
7. M.H. El-Shabouri Positively charged nanoparticles for improving the oral bioavailability of cyclosporine-A Int. J. Pharm. 249 2002 101 108 (Pubitemid 35333436)
8. F.D. Jaeghere, E. Allémann, F. Kubel, B. Galli, R. Cozens, E. Doelker, and R. Gurny Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state J. Control Release 68 2000 291 298 (Pubitemid 30488906)
9. S. Janssens, A.D. Zeure, A. Paudel, J.V. Humbeeck, P. Rombaut, and G.V. Mooter Influence of preparation methods on solid state supersaturation of amorphous solid dispersions: a case study with itraconazole and Eudragit E100 Pharm. Res. 27 2010 775 785
10. Junghanns, A.H. Jens-Uwe, and R.H. Müller Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomed. 3 2008 295 309
11. B.S. Lee, M.J. Kang, W.S. Choi, Y.B. Choi, H.S. Kim, S.K. Lee, J. Lee, and Y.W. Choi Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability Arch. Pharm. Res. 32 2009 1629 1635
12. Y.O. Liu, J.M. Fan, X.Q. Wang, and Q. Zhang Preparation of sorafenib self microemulsifying drug delivery system and its relative bioavailability in rats J. Chin. Pharm. Sci. 20 2011 164 170
13. E.M. Merisko-Liversidge, and G.G. Liversidge Drug nanoparticles: formulating poorly water-soluble compounds Toxicol. Pathol. 36 2008 43 48
14. D.A. Miller, J.C. DiNunzio, W. Yang, J.W. McGinity, and R.O. Williams III Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption Pharm. Res. 25 2008 1450 1459
15. PCT (International application published under the patent cooperation treaty). Nanoparticulate sorafenib formulations. International publication number WO 2008/008733 A2, 2008.
16. C.J.H. Porter, C.W. Pouton, J.F. Cuine, and W.N. Charman Enhancing intestinal drug solubilisation using lipid-based delivery systems Adv. Drug Deliv. Rev. 60 2008 673 691
17. N. Rasenack, H. Hartenhauer, and B.W. Müller Microcrystals for dissolution rate enhancement of poorly water-soluble drugs Int. J. Pharm. 254 2003 137 145 (Pubitemid 36298822)
18. S.B. Ruddy, B.K. Matuszewska, Y.A. Grim, D. Ostovic, and D.E. Storey Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent Int. J. Pharm. 182 1999 173 186 (Pubitemid 29248846)
19. A. Saez, M. Guzmán, J. Molpeceres, and M.R. Aberturas Freeze-drying of polycaprolactone and poly(d,l-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs Eur. J. Pharm. Biopharm. 50 2000 379 387
20. J. Savolainen, K. Järvinen, H. Taipale, P. Jarho, T. Loftsson, and T. Järvinen Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms Pharm. Res. 15 1998 1696 1701 (Pubitemid 28524579)
21. S. Stegemann, F. Leveiller, D. Franchi, H. de Jong, and H. Lindén When poor solubility becomes an issue: from early stage to proof of concept Eur. J. Pharm. Sci. 31 2007 249 261 (Pubitemid 47079001)
22. H. Takeuchi, S. Nagira, H. Yamamoto, and Y. Kawashima Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method Int. J. Pharm. 293 2005 155 164 (Pubitemid 40381089)
23. T. Vasconcelos, B. Sarmento, and P. Costa Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Drug Discov. Today 12 2007 1068 1075 (Pubitemid 350186132)
24. L. Wang, F.D. Cui, and H. Sunada Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method Chem. Pharm. Bull. 54 2006 37 43 (Pubitemid 43036746)
25. X.Q. Wang, J.D. Dai, H. Zhang, X. Zhang, J.C. Wang, and Q. Zhang Absorption mechanism of cyclosporine A loaded pH-sensitive nanoparticles in rats J. Nanosci. Nanotechnol. 8 2008 2422 2431
26. X.Q. Wang, J.D. Dai, Z. Chen, T. Zhang, G.M. Xia, and Q. Zhang Bioavailability and pharmacokinetics of cyclosporine A loaded pH-sensitive nanoparticles for oral administration J. Control Release 97 2004 421 429 (Pubitemid 38802944)
27. X.Q. Wang, J. Huang, J.D. Dai, T. Zhang, W.L. Lu, H. Zhang, X. Zhang, J.C. Wang, and Q. Zhang Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid Int. J. Pharm. 322 2006 146 153 (Pubitemid 44331520)
28. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X. Zhang, P. Vincent, M. McHugh, Y. Cao, J. Shujath, S. Gawlak, D. Eveleigh, B. Rowley, L. Liu, L. Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L.E. Post, G. Bollag, and P.A. Trail BAY 43- 9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res. 64 2004 7099 7109 (Pubitemid 39331023)